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AP4Transcription from the HIV-1 long terminal repeat (LTR) is mediated by numerous host transcription factors.
In this study we characterized an E-boxmotif (RBE1) within the core promoter that was previously implicated
in both transcriptional activation and repression. We show that RBE1 is a binding site for the RBF-2
transcription factor complex (USF1, USF2, and TFII-I), previously shown to bind an upstream viral element,
RBE3. The RBE1 and RBE3 elements formed complexes of identical mobility and protein constituents in gel
shift assays, both with Jurkat T-cell nuclear extracts and recombinant USF/TFII-I. Furthermore, both elements
are regulators of HIV-1 expression; mutations in LTR-luciferase reporters and in HIV-1 molecular clones
resulted in decreased transcription, virion production, and proviral expression in infected cells. Collectively,
our data indicate that RBE1 is a bona ﬁde RBF-2 binding site and that the RBE1 and RBE3 elements are
necessary for mediating proper transcription from the HIV-1 LTR.Molecular Biology, University
ouver, B.C., Canada V6T 1Z3.
. Dahabieh),
(T. Malcolm),
(I. Sadowski).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
HIV-1 gene expression is driven by the long terminal repeat (LTR)
which functions as the viral promoter. Transcription from the LTR is
dependent on host cell machinery and, as such, the viral LTR contains
numerous cis-elements that bind host cell transcription factors
(Reviewed in Coiras et al., 2009; Colin and Van Lint, 2009; Pereira
et al., 2000; Sadowski et al., 2008). As the availability and function of
transcription factors are subject to regulation by cellular dif-
ferentiation and activation state, HIV-1 gene expression and replica-
tion are tightly linked to the host cell's activation state (Sadowski and
Mitchell, 2005). In CD4+ T-lymphocytes, which are one of the main
cell populations producing HIV-1 in vivo, viral transcription is con-
trolled by three main signalling pathways and their cognate down-
stream effectors, including the Ras/MAPK/AP1/Ets (GABP), the PKCθ-
IKK/NF-κB, and the NFAT/calcineurin pathways. Moreover, numerousother transcription factors bind the LTR in the basal or activated states
to modulate gene expression (Pereira et al., 2000).
In addition to AP1, Ets/GABP, and NF-κB, the induction of HIV-1 by
the Ras/MAPK pathway downstream of the T-cell receptor is mediated
by Ras-responsive-binding-factor 2 [RBF-2, (Bell and Sadowski, 1996;
Chen et al., 2005; Malcolm et al., 2007; Malcolm et al., 2008)]. RBF-2 is
a multi-component complex composed of the basic-helix–loop–helix-
leucine zipper (bHLH-ZIP) upstream stimulatory factor (USF) proteins
USF1 andUSF2 and themulti-functional factor TFII-I (Chen et al., 2005;
Estable et al., 1999; Malcolm et al., 2007). The ubiquitously expressed
USF proteins are known to bind canonical E-box elements (CANNTG)
as a USF1/USF2 heterodimer (Sirito et al., 1994); however, we have
previously shown that USF1/2, together with TFII-I, binds a highly-
conserved, atypical site in the HIV-1 U3 enhancer region (ACTGCTGA),
120 nucleotides upstream from the transcriptional start site, termed
Ras-responsive-binding-element 3 [RBE3, (Bell and Sadowski, 1996;
Estable et al., 1996; Estable et al., 1998; Malcolm et al., 2008)].
Moreover, binding of USF to RBE3 shows a requirement for TFII-I as, in
its absence, RBE3 is a low afﬁnity USF binding site in vitro (Chen et al.,
2005; Malcolm et al., 2007, 2008). Functionally, both the viral RBE3
element and the host RBF-2 factor are essential for the transcription
of chromosomally-integrated HIV-1 in response to T-cell activation by
T-cell receptor engagement or phorbol-12-myristate-13-acetate
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addition, integrated LTR reporters with a mutant RBE3 (mRBE3) ele-
ment show reproducible two-fold increases in basal level expression
relative to wild type, suggesting that RBF-2 may bind to the latent,
uninduced LTR and contribute to its repression (Chen et al., 2005;
Malcolm et al., 2008). Indeed, TFII-I has been shown to function as a
repressor by directly interacting with HDAC3 at the c-fos and Vβ
promoters (Wen et al., 2003).
Previous studies have implicated an additional E-box element
(CAGCTG, −21 to −16), between the TATA box and initiator
element of the U3 core promoter, in regulation of HIV-1. This
element, also known as the 3′ E-box, is capable of binding the
CAGCTG-speciﬁc, bHLH-ZIP transcription factor, Activating Protein 4
(AP4) (Hu et al., 1990; Mermod et al., 1988; Ou et al., 1994). In the
context of HIV-1, overexpression of AP4 in HEK 293T cells appears to
cause repression of LTR-driven transcription through multiple
mechanisms: 1) AP4 bound to the 3′ E-box can antagonize the
binding of TATA binding protein (TBP) in vitro, and 2) AP4 can
mediate the recruitment of HDAC1 to the LTR in vivo (Imai and
Okamoto, 2006; Ou et al., 1994). Additionally, our group implicated
this 3′ E-box element, as well as the RBE3 sequence, in mediating the
response to v-Ras activated LTR expression and termed the site Ras-
responsive-binding-element-1 [RBE1, (Bell and Sadowski, 1996)].
Indirect evidence suggested that RBE1 and RBE3 may bind the same
factor, RBF-2, however this possibility was never tested directly (Bell
and Sadowski, 1996).
Given the sequence similarity between the viral cis-acting elements
RBE1 and RBE3 (core GCTG motif) and the ability of both to positively
mediate the response of the LTR to v-H-Ras (Bell and Sadowski, 1996),
we hypothesized that the transcription factor complex RBF-2 binds to
both RBE1 and RBE3. In this study, we analyzed RBE1-bound complexes
formed with T-cell nuclear extracts as well as recombinant proteins,
and found that the complex formed at RBE1 contained the RBF-2
components USF1, USF2 and TFII-I. This sequence was capable of
competing for RBF-2 bound to RBE3 in electrophoretic mobility shift
assays (EMSA), and formed a complex of identical mobility as RBF-2
bound to RBE3.We also examined the effect ofmutant RBE elements on
transcription from the HIV-1 LTR. RBE1 and RBE3 mutants exhibited a
modest but reproducible decrease in reporter gene activity while the
RBE1/3 double mutant LTR displayed an additive reduction in activity.
These observations were extended to virion production experiments
and reporter cell infections using full-length HIV-1 molecular clones,TGCATCCGGAGTACTTCAAGAACTGCTGACATCGAG
GGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGC
TFII-I 
RBE3 
USF1 USF2 
Nuc-0 
RBF-2 
mRBACTGCACT
SP1 SP1 SP1 
-150 
-79 SP1 
Fig. 1. Schematic representation of the HIV-1 LTR (LAI) and its highly conserved cis-elements
within boxes. Core nucleotides shared between RBE1 and RBE3 are underlined. Nuc-0 and
(arrow) denotes the transcriptional start site.which were consistent with ﬁndings from the transient LTR-reporter
assays. Collectively, our results indicate that RBE1 is a novel binding site
for the transcription factor complex RBF-2 (USF1/2 and TFII-I).
Furthermore, our data suggests that the highly conserved RBE1 and
RBE3 elements ﬂanking the HIV-1 enhancer contribute to controlling
proper expression of viral gene products in infected cells.
Results
Proteins in Jurkat T-cell nuclear extracts form complexes of identical
mobility at both RBE3 and RBE1 sites
Given the similarity between the RBE1 and RBE3 sequences (core
GCTG motif, Fig. 1), we examined complexes bound to this region of
the LTR in Jurkat T-cells. We compared protein–DNA complexes
formed with Jurkat nuclear extract at both RBE1 and RBE3 by EMSA. A
labelled RBE1-containing oligonucleotide probe formed a complex of
identical mobility to RBE3-bound RBF-2. Although complexes of
identical mobility were formed using both probes, we noted a
substantially lower gel shift intensity for RBE1 as compared to RBE3
(Fig. 2A, compare lanes 1 and 4). Binding of these complexes to both
probes could be competed by unlabeled RBE1 or RBE3 oligos (Fig. 2A,
lanes 2–3 and 5–6), suggesting that the complexes have similar
sequence speciﬁcity. Additionally, we noted that the RBE1 oligonu-
cleotide produced a slower migrating and uncharacterized complex
that was previously designated the TATA binding complex [TBC, (Bell
and Sadowski, 1996)]. The RBE3, but not the RBE1, oligonucleotide
also formed a complex with another transcription factor YY1, which is
consistent with previous data (Malcolm et al., 2008). These observa-
tions indicate that the regions of the LTR containing RBE1 and RBE3
both form complexes with proteins in Jurkat nuclear extract that have
similar sequence speciﬁcity, in addition to other factors.
RBE1-Jurkat nuclear extract complexes contain RBF-2 and are distinct
from AP4
The RBE1 cis-element spans a consensus E-box previously shown
to bind AP4 (Imai and Okamoto, 2006; Ou et al., 1994). Given the fact
that at RBE1 we observed a complex with identical properties to
RBF-2, we probed the identity of proteins bound to oligonucleotides
spanning this region using speciﬁc antibodies. We conﬁrmed that
AP4, TFII-I, USF1, and USF2 were present in Jurkat T-cell nuclearNFAT NFAT 
CTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAG
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Fig. 2. Proteins in Jurkat nuclear extract produce identical complexes with RBE1- and RBE3-containing oligonucleotides. A: EMSA was performed with Jurkat nuclear extracts and
labelled RBE3 (lanes 1–3) or RBE1 probes (lanes 4–6). Unlabeled RBE3 (lanes 2 and 5) or RBE1 (lanes 3 and 6) competitor oligos were added at 100-fold molar excess. Migration of
previously deﬁned USF, TFII-I, YY1, TATA-binding complexes and non-sequence speciﬁc bands are indicated. B: Jurkat nuclear extracts (10 μg) were separated on a 12% SDS-PAGE gel
and transferred to a nitrocellulose membrane. Proteins were detected by immunoblotting with α-AP4, α-TFII-I, α-USF1, or α-USF2 antibodies. C: EMSA was performed with Jurkat
nuclear extracts and a labelled RBE1 probe. RBE1 (lane 3), mutant RBE1 (lane 4), mutant AP4 (lane 5), RBE3 (lane 6), or mutant RBE3 (lane 7) unlabelled competitor oligos were
added at 50-fold molar excess. 1 μg of antibodies to USF1 (lane 8), USF2 (lane 9), AP4 (lane 10), or TFII-I (lane 11) were added to determine complex constituents. 1 μg of rabbit IgG
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59M.S. Dahabieh et al. / Virology 418 (2011) 57–66extracts using immunoblotting (Fig. 2B). We next performed EMSA
with a radiolabelled RBE1-containing oligo and Jurkat nuclear
extracts. In the absence of any competitor oligos or antibodies, we
observed complexes corresponding to both RBF-2 as well as the
previously described TBC complex (Fig. 2C, lane 2). The former
complex could be competed away by excess unlabelled RBE1
(Fig. 2C, lane 3) or RBE3 oligonucleotides (Fig. 2C, lane 6) but not
by oligonucleotides bearing a mutation within RBE1 that, in con-
junction with a mutation in RBE3, was previously shown to prevent
stimulation of the LTR by v-Ha-Ras (mRBE1—Fig. 2C, lane 4) (Bell
and Sadowski, 1996), a mutation shown to inhibit binding of AP4
(mAP4—Fig. 2C, lane 5) (Imai and Okamoto, 2006; Ou et al., 1994), or
a mutation of the RBE3 element (mRBE3—Fig. 2C, lane 7) (Malcolm
et al., 2008). These results indicate that the complex formed withJurkat nuclear extracts at RBE1 speciﬁcally recognizes the 3′ E-box
element ﬂanking the TATA box and likely contains RBF-2. To further
examine the interaction of RBF-2 at RBE1, we added antibodies
against RBF-2 constituents as well as AP4 to the EMSA reactions.
Antibodies against USF1 (Fig. 2C, lane 8) and USF2 (Fig. 2C, lane 9)
both prevented formation of the RBF-2 complex, whereas an
antibody against TFII-I formed a supershifted species (Fig. 2C,
lane 11). Surprisingly, antibodies against AP4 did not disrupt any
of the complexes formed with the RBE1 oligonucleotide, including
the RBF-2 complex; moreover, no supershifted species were ob-
served with the AP4 antibody (Fig. 2C, lane 10). Taken together,
these results suggest that at endogenous levels of protein in Jurkat T-
cell nuclear extracts, RBE1 is preferentially bound by RBF-2 rather
than by AP4, and that RBE1 is a bona ﬁde RBF-2 binding site.
60 M.S. Dahabieh et al. / Virology 418 (2011) 57–66Recombinant USF and TFII-I bind an RBE1 containing oligonucleotide
To conﬁrm that USF and TFII-I are capable of binding to the RBE1
element 3′ of the TATA box, we performed EMSA with recombinant
USF1 and USF2 produced in baculovirus infected Sf21 insect cells.
When co-expressed, USF1 and USF2 produced three complexes bound
to an RBE3-containing oligonucleotide representing USF2 homodi-
mers, USF1/USF2 heterodimers, and USF1 homodimers (Fig. 3A, lane
1). The identity of these complexes was veriﬁed by the inclusion of α-
FLAG and α-USF2 antibodies, which caused a supershift of FLAG-
tagged USF1 (Fig. 3A, lane 5) and native USF2 (Fig. 3A, lane 6). Binding
of each of the complexes could be competed with unlabeled wild type
RBE3 oligonucleotide (Fig. 3A, lane 2), but not an RBE3 mutant
oligonucleotide (Fig. 3A, lane 3). Importantly, complexes with
identical mobility were observed in EMSA reactions using an RBE1-
containing probe (Fig. 3A, lanes 7–12). Binding of the USF complexes
could be competed by excess unlabeled wild type RBE3 or RBE1
oligonucleotides (Fig. 3A, lanes 8 and 10), but not by mutant RBE3
oligonucleotides (Fig. 3A, lane 9). Furthermore, complexes formed
with recombinant USF on the RBE1 oligo were supershifted by the
inclusion of speciﬁc antibodies (Fig. 3A, lanes 11 and 12). These
ﬁndings suggest that the RBE1 E-box element immediately down-A 
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are representative of two independent experiments.stream of the TATA box is bound by recombinant USF1/2 hetero-
dimers, consistent with the results obtained with Jurkat nuclear
extracts (Fig. 2).
TFII-I enhances the USF–RBE1 interaction in vitro
To examine the involvement of TFII-I in binding of USF to RBE1, we
determined whether recombinant TFII-I was capable of stimulating
binding of USF to RBE1 in an EMSA reaction, similar to the effect
previously shown for binding of USF to RBE3 (Malcolm et al., 2008).
We found that addition of TFII-I at an approximately 10-fold molar
excess caused a 2–3-fold enhancement of USF binding (Fig. 3B, lanes
2–7). This effect is somewhat smaller than the 10-fold enhancement
by TFII-I for binding of USF to the non-canonical RBE3 site (Malcolm
et al., 2008). This difference is likely attributed to the fact that RBE1
contains an E-Box motif (CAGCTG), to which USF heterodimers are
capable of binding on their own (Corre and Galibert, 2005). In-
terestingly, recombinant TFII-I itself formed several complexes with
the RBE1 probe in EMSA reactions (Fig. 3B, lane 13), which might
reﬂect binding of TFII-I monomers to multiple sites, or as a multimer
to a single site. We have not fully characterized the DNA binding
speciﬁcity for TFII-I in this region of the LTR, but we noted that a
mutation within the E-box motif (CAGCTGC to CAGggtg) prevented
competition for binding to USF1 and USF2, but not to the TFII-I speciﬁc
complex (lane 12). This suggests that TFII-I must bind to sequences
ﬂanking the E-box. Consistent with this, it was previously demon-
strated that USF and TFII-I bind cooperatively at both E-box and Inr
elements within the Adenovirus major late (AdML) promoter (Roy
et al., 1991). These results, taken together with previous observations
(Bell and Sadowski, 1996; Chen et al., 2005; Malcolm et al., 2007,
2008), conﬁrm that USF and TFII-I are bound together at both RBE1
and RBE3, which ﬂank the core promoter and enhancer regions of the
HIV-1 LTR.
Interaction of RBF-2 at RBE1 can be observed by DNaseI footprinting
In order to conﬁrm that USF binds directly overlapping the E-box
element spanning RBE1, we performed DNaseI footprinting analysis of
recombinant RBF-2 constituents on the core HIV-1 LTR promoter
region. A template of approximately 120 nucleotides, spanning the 5′
most SP1 binding site (−82) to the TAR stem loop (+42)was used for
footprinting with recombinant USF1/2 and TFII-I expressed in bacu-
lovirus infected Sf21 insect cells. In the absence of TFII-I, USF1/2
protected a region of approximately 20 nucleotides centered over the
RBE1 E-box (Fig. 4A, lanes 3 and 4). Consistent with the EMSA results
shown above, addition of TFII-I to footprinting reactions containing a
minimal amount of USF1/2 caused enhanced protection of this same
region of the LTR (Fig. 4A, lanes 7 and 8). However, TFII-I alone did not
produce speciﬁc protection, despite the above observation that it
forms multiple complexes with the RBE1 probe in EMSA (Fig. 3B).
Similar observations were noted previously for interaction of TFII-I
with the AdML initiator element (Roy et al., 1991), and with the
upstream HIV-1 RBE3 element (Malcolm et al., 2008).
Binding of USF/TFII-I to RBE1 produced a footprint larger than that
of the E-box consensus sequence itself (Fig. 4A, lanes 3–8). USF, alone
or in combination with TFII-I, protected a region of approximately 20–
25 nucleotides including the TATA box and the RBE1 motif, as well as
approximately ﬁve nucleotides on both sides. This result is similar to
footprinting assays for USF/TFII-I binding to the RBE3 element and USF
to the upstream E-box (−166 to −161), where binding protects
approximately 20 nucleotides centered over both elements (Malcolm
et al., 2008). This may reﬂect natural sites of non-speciﬁc contact
between USF and its cognate binding site. Indeed, it has been pre-
viously described that USF protects approximately 20 nucleotides on
the AdML (Roy et al., 1991) and Human Apolipoprotein C-III
promoters (Pastier et al., 2002). Mutation of the RBE1 element
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61M.S. Dahabieh et al. / Virology 418 (2011) 57–66completely abolished protection by USF in DNaseI footprinting assays
(Fig. 4B, lanes 3-8), either alone or in combination with TFII-I. Taken
together, DNaseI footprinting supports the contention that RBE1
serves as a binding site for RBF-2.
RBE elements mediate transcriptional activation in transient assays
Despite the extensive sequence diversity of HIV-1, the RBE1 and
RBE3 sequences are highly conserved amongst clinical isolates, sug-
gesting that these two elements are important for HIV-1 replication
(Estable et al., 1996, 1998, 1999; Jeeninga et al., 2000; Malcolm et al.,
2008). Since USF and TFII-I have been shown to have both activating
and repressive effects depending on context [promoter, cell type, and
cellular activation state—reviewed in (Corre and Galibert, 2005; Roy,
2007; Yang et al., 2002)], and the viral RBE1 and RBE3 elements are
both bound by RBF-2, we sought to evaluate the role of these elements
in the regulation of HIV-1 expression. In order to test the role of the
RBE elements in mediating both basal transcription as well as Tat-
activated transcription, we created LTR-luciferase reporter constructs
bearing mutant RBE elements, both with and without the TAR stem
loop. Given the stimulatory effect of Tat-transactivation when TAR is
present (Berkhout et al., 1989), we transiently transfected HEK 293T
cells with the LTR-luciferase reporter constructs both in the presence
and absence of the viral transactivator Tat. Fig. 5 shows that,
regardless of TAR and Tat, the RBE3 and RBE1/RBE3 mutant LTRs
resulted in a two-fold decrease in reporter activity compared to wild
type. Additionally RBE1 mutant reporters exhibited a more modest
25% reduction in activity relative to wild type. This pattern of activity
amongst the LTR reporters was consistent between all combinations
of TAR and Tat tested (Fig. 5). When TAR and Tat were both present,
luciferase activity was strongly induced (approximately 15-fold
increase compared to the expression level measured in the absence
of Tat). Furthermore, the same relative expression pattern was
apparent among wild type and mutant promoters suggesting thatthe RBE elements do not alter the ability of the LTR to respond to Tat-
mediated activation but rather regulate basal level activity (Fig. 5).
Taken together, these data conﬁrm that intact RBE elements are
required for efﬁcient LTR transcription and therefore, may play a role
in regulating HIV-1 expression.
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In order to assess the role of the RBE elements in HIV-1 expression
and production, we constructed full-length LAI molecular clones with
mutations of the RBE elements in only the 3′ LTR or in both the 3′ and
5′ LTRs. As expression of the molecular clones is driven by the 5′ LTR,
mutations present in the 3′ LTR will only affect LTR activity after
reverse transcription and infection of target cells (Fig. 6A). We
generated wild type and mutant viral stocks by transfection of 293T
cells with a low amount of DNA (50 ng) and quantiﬁed virion pro-
duction in the supernatants by p24 ELISA (Fig. 6B). As expected, we
observed no difference in p24 levels between the 3′ LTR mutants and
wild type (Fig. 6B, black bars). In contrast to the 3′ LTRmutants, virion
production was affected by the 5′ LTR mutants. The 5′ LTR RBE3 and
RBE1 single mutants showed a 25 and 60% decrease in levels of p24,
respectively, which was further reduced in the RBE1/3 double mutant
(approximate ﬁve-fold reduction, Fig. 6B, white bars). These data are
consistent with the results of the LTR-luciferase assays and support
the idea that the RBE elements may play a role in mediating proper
HIV-1 expression.
We next wanted to examine the effects of the mutant RBE ele-
ments in the context of integrated proviruses by comparing the
viruses' expression in a single cycle assay using TZM-bl reporter cells.
TZM-bl cells are a HeLa-derived cell line that express the HIV-1 entry
receptors CD4, CXCR4 and CCR5, and contain an integrated HIV-1gag
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the effects of the RBE mutations may be affected by concentration
(DNA or virus), although the consequences of this are currently
unknown. Collectively, our results indicate a role for the RBE3 and
RBE1 elements in the proper regulation of HIV-1 gene expression
through activation of LTR-driven transcription.
Discussion
HIV-1 exploits host cell transcription factors to regulate its initial
expression from the proviral LTR. Different mechanisms ensure
transcription in different cell types and cellular activation states (Pereira
et al., 2000; Sadowski et al., 2008). In activated T lymphocytes, a
combination of factors responsive to T-cell signalling pathways (NF-κB,
NFAT, AP1 and GABP/Ets) permits robust transcription of the provirus
(Brooks et al., 2003; Robichaud et al., 2002). Conversely, reversion to a
resting memory CD4+ T-cell state results in repression of the provirus
through reorganization of the LTR into repressive chromatin (Han et al.,
2007; Mok and Lever, 2007), thereby leading to post-integration
molecular latency (Reviewed in Coiras et al., 2009; Colin and Van Lint,
2009; Lassenet al., 2004;Richmanet al., 2009; Tronoet al., 2010).Among
theelements thatmediate transcriptional regulationof theHIV-1 LTRare
two elements that ﬂank the core viral enhancer, RBE1 and RBE3.
In this study, we demonstrated that the RBE1 element is a novel
binding site for the transcription factor complex RBF-2. In both EMSA
and DNaseI footprinting experiments, RBF-2 constituents USF1, USF2
and TFII-I bound the RBE1 E-box (Figs. 2–4). Of note, we were unable
to detect AP4 in complexes bound to RBE1 in EMSA experiments with
Jurkat T-cell nuclear extracts, whereas USF1, USF2 and TFII-I did form
complexes with this element as detected by speciﬁc antibodies
(Fig. 2C). We were able to detect AP4 protein expression in Jurkat
nuclear extracts by immunoblotting (Fig. 2B), and it is possible that
binding of RBF-2 is mutually exclusive of AP4. Additionally, the effect
of AP4 on transcription from the LTR may be modiﬁed by the
signalling state of the cell, dictated by various post translational
modiﬁcations, and/or be subject to regulation by other transcription
factors recruited to the promoter. As such, whether or not RBF-2 is a
binding partner or competitor of AP4, it may be that at endogenous
levels of Jurkat T-cell nuclear protein, the effect of AP4 is masked by
the action of RBF-2. Although further work will be needed to elucidate
this relationship, we clearly observe that single and double mutations
of RBE1 and RBE3 decrease transcription from the LTR, virion pro-
duction, and proviral expression (Figs. 5 and 6). Importantly, theseeffects are the opposite of what would be expected for RBE1 if a
repressor protein like AP4 is the sole factor binding this site.
Interestingly, binding of multiple host transcription factors to the
same cis-element within the HIV-1 LTR has been observed before,
most notably the duplicated NF-κB/NFAT sites (Bates et al., 2008; Cron
et al., 2000; Kinoshita et al., 1997; Koken et al., 1992; Michael et al.,
1994).
Analyses of transcription, virion production and proviral expression
suggest that, together, the RBE1 and RBE3 elements mediate the proper
transcriptional activation of HIV-1. Given that the two elements bind
the same factor in vitro, it is not surprising that these elements would
have similar effects on LTR-driven transcription. However, previous
work by our group using stably integrated LTR reporters in clonal cell
lines has shown that RBE3 mutants exhibit a modest but reproducible
increase in basal transcription, thus suggesting a dual role for RBE3 in
which it can also act as amediator of transcriptional repression (Chen et
al., 2005;Malcolm et al., 2007, 2008).While these differences could be a
result of the lack of proper chromatin environment in transient assays,
we note that the results of our transient experiments were consistent
with assays of proviral expression in TZM-bl cells. It is also interesting
to note that the Jurkat cell lines used in our previous studies were
subject to long-term passaging prior to the assessment of promoter
activity. This time framewould allow the integrated retroviral reporters
to be epigenetically silenced (Ellis, 2005), and this silencing could be
differentially affected by the RBE3 mutation, thus implicating RBE3 in
mediating long-term transcriptional repression. Reduced silencing of
the mutant RBE3 reporter could be caused by less efﬁcient RBE3–RBF-2
mediated recruitment of silencing factors to the LTR or due to the
reduced initial LTR activity prior to the establishment of silencing. In
both scenarios, the overall level of silencing in themutant LTRwould be
reduced relative to wild type, and the RBE3 element, along with RBF-2,
would appear to mediate transcriptional repression. Further work is
needed to elucidate the role of RBF-2 in mediating proviral silencing
and latency as well as to reconcile the duality of function RBF-2 seems
to possess.
Regardless of any involvement in epigenetic silencing, our data
indicate that both the RBE1 and RBE3 elements are involved in
coordinating efﬁcient LTR activity; thus, future experiments are also
needed to elucidate the precise mechanism(s) of RBE-mediated
transcriptional control. Speciﬁcally, chromatin immunoprecipitation
(ChIP) experiments coupled with siRNA knockdown of RBF-2 factors
should allow for the elucidation of RBF-2 function at RBE1 and RBE3 in
integrated, chromatin bound LTRs, both in the basal and activated
states. However, the close proximity of the RBE elements (~100 bp
apart), and the presence of an additional USF binding site ~40 bp
upstream of RBE3 (Coiras et al., 2009; Colin and Van Lint, 2009; Lassen
et al., 2004; Richman et al., 2009; Trono et al., 2010), makes it
technically challenging to use ChIP and siRNA analysis to delineate
between RBF-2 bound at both RBE elements. It is interesting to note
however, that in RBE1 and RBE3, the HIV-1 LTR contains two highly
conserved sites that bind the same factor (RBF-2). In vitro evidence
suggests that the leucine zipper domain of USF is capable of forming
higher-order homotetramer complexes at intracellular protein con-
centrations (Ferre-D'Amare et al., 1994). While it is unclear if this
interaction occurs in vivo, or how the presence of TFII-I would impact
potential interactions, higher order USF structures may potentiate LTR
looping interactions that could contribute to additional levels of
transcriptional regulation.
Fully characterizing the function of RBF-2 at the RBE elements, as
well as other HIV-1 transcriptional regulators bound to the LTR, is of
considerable clinical interest since modulating their functions may
produce novel therapeutic interventions that target not only replicat-
ing viruses but also latent HIV-1 proviruses. Novel approaches may
allow for targeted and controlled reactivation of latent reservoirs by
inhibiting transcriptional repressors and/or stimulating transcription-
al activators. Conversely, it may be possible to permanently repress
Table 2
Single stranded oligonucleotides used in this study.
Name Sequence Use
oMD018 AAACTGCAGCCAGGGAGGCGTGGC pLAI forward footprint primer
oMD019 AAACGGCCGGAGAGCTCCCAGGCT pLAI reverse footprint primer
oMD099 CAGCATCTCGAGACCTGG 3′ LTR forward cloning primer
oMD102 CACCTGACGTCTAAGAAACC 3′ LTR reverse cloning primer
oMD105 ATCCGCTCTAGAACTAGTGGATC 5′ LTR forward cloning primer
oMD106 GCCGTGCGCGCTTCAGCAAGC 5′ LTR reverse cloning primer
oTM273 CTTCAAGAACTGC
actCATCGAGCTTGCTAC
RBE3 mutagenic primer +
oTM274 GTAGCAAGCTCGATG
agtGCAGTTCTTGAAG
RBE3 mutagenic primer −
oMD100 CAGATGCTGCATATAAGCAG
ggtgTTTTTGCCT
GTACTGGGTCT
RBE1 mutagenic primer +
oMD101 AGACCCAGTACAGGCAAAAA
caccCTGCTTATATGCAGCATCTG
RBE1 mutagenic primer −
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manner. Thus, the development of novel therapeutics to robustly
modulate HIV-1 transcription would provide welcome new weapons
for use in the eradication of HIV-1.
Materials and methods
Protein–DNA interaction assays
USF/TFII-I EMSAswere performed as previously described (Malcolm
et al., 2008). For EMSA and DNaseI footprinting, USF1, USF2 and TFII-I
were produced by expression in Sf21 insect cells from baculovirus
vectors (Chen et al., 2005). Recombinant SP1 was obtained commer-
cially (Promega). Jurkat nuclear extracts for EMSA reactions were pre-
pared as previously described (Li et al., 1991). Antibodies used were as
follows: AP4 (ab28512, Abcam), TFII-I (Chen et al., 2005), USF1 (H-86,
Santa Cruz), and USF2 (N-18, Santa Cruz). Proteins were detected in
10 μg of Jurkat nuclear extract by immunoblotting with the antibodies
listed above (1 μg/mL, 4 °C overnight). Double stranded oligos used for
EMSA are listed in Table 1.
DNaseI footprinting templates were produced from wild type (LAI)
or mutant RBE1 (mRBE1) LTRs by EagI/PstI digestion of plasmids pBS-
FPLAI or pBS-FPLAImRBE1 respectively, and subsequent gel extraction.
Plasmids pBS-FPLAI or pBS-FPLAImRBE1 were created by PCR amplifying a
120 bp fragment of the LTR from either pLAI or pLAI-mRBE1 with oligos
oMD018/oMD019 (Table 2) and subcloning into the EagI/PstI sites of
pBluescriptII KS+[Fermentas, (Alting-Mees et al., 1992)]. The puriﬁed
fragmentswere labelled at the 3′ end (EagI overhang) by endﬁllingwith
Klenow (New England Biolabs) in the presence of [α-32P]dCTP and
[α-32P]dGTP (Perkin Elmer). Unincorporated label was removed using a
Sephadex G-50 spin column (GEHealthcare) and the probewas puriﬁed
using a DNA spin column (Qiagen). Binding reactions and DNaseI
(Promega)digestionswereperformedaspreviouslydescribed (Malcolm
et al., 2008) with the indicated amounts of USF1, USF2, TFII-I, and SP1
protein and approximately 4×104 counts per minute (cpm) of labelled
LTR probe. After incubating the proteins with the DNA probe for 30 min
at 4 °C, reactions were incubated with 1.75 units of DNaseI for 45 s at
room temperature prior to the addition of 100 μl DNaseI stop solution
(0.2 M NaCl, 20 mM EDTA, 1% SDS, 200 μg/mL proteinase K), and
incubation at 55 °C for 1 h. Followingextractionwith phenol/chloroform
and ethanol precipitation, radioactivity in the pellets wasmeasured in a
Beckman LS 3801 scintillation counter. Samples were re-suspended in
sequencing loading buffer (0.2 mg/mL bromophenol blue and xylene
cyanol, 25 mM EDTA, 90% deionized formamide), denatured at 100 °C
for 2 min, and approximately 2.5×104 cpm were analyzed per lane on
an 8% polyacrylamide-urea gel alongside a G+A sequencing ladder
produced as previously described (Bencini et al., 1984).
Cell culture
Transformed cell lines: Jurkat T-cells as well as the TZM-bl reporter
cells were obtained from the National Institutes of Health (NIH) AIDS
Reagent Program (Derdeyn et al., 2000; Platt et al., 1998; Smith et al.,Table 1
Double stranded oligonucleotides used in this study for EMSA.
Name Sequence
RBE3 GATCCTTCAAGAACTGCTGACATCGAGCTTTCTC
RBE1 ATGCTGCATATAAGCAGCTGCTTTTTGCCTGTACT
mRBE3 GATCCTTCAAGAACTGCactCATCGAGCTTTCTC
mRBE1 ATGCTGCATATAAGCAGggtgTTTTTGCCTGTACT
mAP4 ATGCTGCATATAAGCAGCTcCTTTTTGCCTGTACT
The RBE3 and RBE1 core elements are indicated in bold (top two lines). Mutations in
competitors are indicated by lower case bold. For labeling purposes, all probe oligos
contain an AATT single strand overhang at the 5′ end (not shown).1984; Takeuchi et al., 2008; Wei et al., 2002; Weiss et al., 1984).
Human embryonic kidney (HEK) 293T and Sf21 insect cells were
obtained from the American Type Culture Collection. Jurkat cells were
grown in RPMI 1640 (Sigma) plus 10% fetal bovine serum (Sigma)
supplemented with penicillin (100 U/mL) and streptomycin
(100 mg/mL) (Gibco), and maintained in a humidiﬁed 37 °C, 5% CO2
atmosphere. HEK 293T and TZM-bl cells were grown under standard
conditions as previously described (Harari et al., 2009). Sf21 insect
cells were grown in Sf-900 II insect media (Gibco) plus 10% fetal
bovine serum and maintained at 27 °C.Transient luciferase expression assays
To measure promoter activity, the 3′ LTR from the molecular clone
LAI was cloned either with or without the TAR stem loop into the
promoter-less reporter vector pGL3-Basic (Promega). To create re-
porterswith TAR, the 3′ LTRwas PCR ampliﬁedwith oligos oMD099 and
oMD102 (Table 2) from LAI molecular clones and inserted into the
KpnI/HindIII sites of pGL3-Basic to create pGL3TAR-WT, pGL3TAR-
mRBE3, pGL3TAR-mRBE1, and pGL3TAR-mRBE1/3. To create the
identical reporters without TAR, the ampliﬁed LTR was instead cloned
into the KpnI/SacI sites of pGL3-Basic. The LTR-luciferase reporter
constructs used are summarized in Table 3. For transient assays, 10 ngof
the pGL3 reporter plasmid along with 10 ng of either pcDNA3.1+
(Invitrogen) or pcDNA-Tat was transfected into 293T cells using
polyethylenimine (Polysciences) as previously described (Durocher
et al., 2002). Transfectionswereperformed in96well plates seededwith
2×104 cells per well 24 h prior to transfection. Luciferase activity was
measured 24 h post transfection with the Bright-Glo Luciferase Assay
System (Promega) asper themanufacturer's instructions; 96well plates
were read in a Victor X3 plate luminometer (Perkin Elmer).Viral strains
Plasmid pLAI, containing the complete HIV-1 LAI genome, was
provided by Dr. Ben Berkhout (Peden et al., 1991). The RBE1
(CAGCTGC to CAGggtg), and RBE3 (ACTGCTGA to ACTGCact) muta-
tions were produced by PCR mediated site-directed mutagenesis
using the oligonucleotides indicated in Table 2, and then cloned into
the unique XhoI and AatII restriction sites in the 3′ LTR of pLAI to create
pLAI-mRBE1, pLAI-mRBE3, and pLAI-mRBE1/3. Similarly, mutations
in the 5′ LTR of LAI were created by PCR mediated site-direct
mutagenesis and cloned into the unique XbaI and BssHII sites. All
mutations in the 3′ and 5′ LTRs were conﬁrmed by DNA sequencing
using the primers oMD099 and oMD105, respectively (Table 2). The
HIV-1 molecular clones used in this study are summarized in Table 3.
Table 3
Plasmids used in this study.
Name Description
pLAI HIV-1 LAI molecular clone
pLAI-mRBE3 LAI with mRBE3 site in the 3′ LTR
pLAI-mRBE1 LAI with mRBE1 site in the 3′ LTR
pLAI-mRBE1/3 LAI with mRBE1 and
mRBE3 sites in the 3′ LTR
pLAI-mRBE3-5′ LAI with mRBE3 site in the 5′ LTR and 3′ LTR
pLAI-mRBE1-5′ LAI with mRBE1 site in the 5′ LTR and 3′ LTR
pLAI-mRBE1/3-5′ LAI with mRBE1 and mRBE3 sites in the 5′ LTR and 3′ LTR
pGL3-Basic Luciferase reporter without promoter (Promega)
pGL3TAR-WT pGL3-Basic with WT LAI 3′ LTR fragment (KpnI/HindIII)
pGL3TAR-mRBE3 pGL3-Basic with mRBE3 LAI 3′ LTR fragment (KpnI/HindIII)
pGL3TAR-mRBE1 pGL3-Basic with mRBE1 LAI 3′ LTR fragment (KpnI/HindIII)
pGL3TAR-mRBE1/3 pGL3-Basic with mRBE1/3 LAI 3′ LTR fragment (KpnI/HindIII)
pGL3-WT pGL3-Basic with WT LAI 3′ LTR fragment (KpnI/SacI)
pGL3-mRBE3 pGL3-Basic with mRBE3 LAI 3′ LTR fragment (KpnI/SacI)
pGL3-mRBE1 pGL3-Basic with mRBE1 LAI 3′ LTR fragment (KpnI/SacI)
pGL3-mRBE1/3 pGL3-Basic with mRBE1/3 LAI 3′ LTR fragment (KpnI/SacI)
pBluescriptII KS+ Cloning vector (Fermentas)
pBS-FPLAI pBluescriptII KS+ with LAI RBE1 Eag1/Pst1 PCR fragment
pBS-FPLAImRBE1 pBluescriptII KS+ with LAI mutant RBE1 Eag1/Pst1 PCR fragment
pcDNA3.1+ CMV-based mammalian expression vector (Invitrogen)
pcDNA-Tat pcDNA3.1+ based HIV-1 LAI Tat expression plasmid
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Wild type and mutant RBE viral stocks were produced by
transfection of molecular clones into HEK 293T cells using poly-
ethylenimine as previously described (Durocher et al., 2002). The
molecular clone used and amount transfected are indicated in the
details of each experiment. HEK 239T cells were transfected in a 24
well plate seeded 24 h prior to transfection with 1.5×105 cells per
well, except for the experiment in Fig. 6C where cells were transfected
in a 96 well plate seededwith 2×104 cells per well. Viral supernatants
were harvested 48 h post transfection, clariﬁed by ﬁltration (0.45 μm)
and stored at −80 °C until use. HIV-1 p24 gag in the culture
supernatant was quantiﬁed using a commercial ELISA kit as per the
manufacturer's instructions (XpressBio). Proviral expression of the
viruses was tested by infecting TZM-bl reporter cells and measuring
production of β-galactosidase as previously described (Harari et al.,
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